353 related articles for article (PubMed ID: 31990705)
1. Antiretroviral therapy in older people with HIV.
Richterman A; Sax PE
Curr Opin HIV AIDS; 2020 Mar; 15(2):118-125. PubMed ID: 31990705
[TBL] [Abstract][Full Text] [Related]
2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
3. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
4. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
5. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
7. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
8. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
9. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
[TBL] [Abstract][Full Text] [Related]
10. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
11. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
12. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
[TBL] [Abstract][Full Text] [Related]
13. [Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
Rolón MJ; Figueroa MI; Sued O; Cahn P
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():7-11. PubMed ID: 25542869
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
Rutherford GW; Horvath H
PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
[TBL] [Abstract][Full Text] [Related]
15. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
16. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.
Neesgaard B; Mocroft A; Zangerle R; Wit F; Lampe F; Günthard HF; Necsoi C; Law M; Mussini C; Castagna A; Monforte AD; Pradier C; Chkhartisvilli N; Reyes-Uruena J; Vehreschild JJ; Wasmuth JC; Sönnerborg A; Stephan C; Greenberg L; Llibre JM; Volny-Anne A; Peters L; Pelchen-Matthews A; Vannappagari V; Gallant J; Rieger A; Youle M; Braun D; De Wit S; Petoumenos K; Borghi V; Spagnuolo V; Tsertsvadze T; Lundgren J; Ryom L;
PLoS One; 2020; 15(12):e0243625. PubMed ID: 33382756
[TBL] [Abstract][Full Text] [Related]
17. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
[TBL] [Abstract][Full Text] [Related]
18. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
19. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
20. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
Milanés-Guisado Y; Gutiérrez-Valencia A; Muñoz-Pichardo JM; Rivero A; Trujillo-Rodriguez M; Ruiz-Mateos E; Espinosa N; Roca-Oporto C; Viciana P; López-Cortés LF
J Antimicrob Chemother; 2020 Jan; 75(1):200-207. PubMed ID: 31617904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
